Apollo Medical (AMEH) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Apollo Medical (OTCMKTS:AMEH) from a hold rating to a buy rating in a report released on Tuesday morning. They currently have $21.00 target price on the healthcare company’s stock.

According to Zacks, “Apollo Medical Holdings, Inc. engages in the provision of healthcare services. It offers integrated care, inpatient and physician alignment solutions. The company focuses on physicians providing high-quality medical care, population health management and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Apollo Medical Holdings, Inc. is headquartered in Glendale, CA. “

Shares of AMEH stock opened at $17.38 on Tuesday. Apollo Medical has a fifty-two week low of $7.95 and a fifty-two week high of $30.00.

Apollo Medical (OTCMKTS:AMEH) last posted its quarterly earnings results on Wednesday, November 14th. The healthcare company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.09 by $0.15. The firm had revenue of $167.28 million for the quarter.

In other Apollo Medical news, CEO Warren Hosseinion sold 22,900 shares of the business’s stock in a transaction that occurred on Thursday, August 30th. The shares were sold at an average price of $15.94, for a total transaction of $365,026.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Adrian Vazquez sold 221,597 shares of the business’s stock in a transaction that occurred on Wednesday, November 21st. The stock was sold at an average price of $17.55, for a total transaction of $3,889,027.35. The disclosure for this sale can be found here. Insiders have sold a total of 373,071 shares of company stock valued at $6,441,007 in the last quarter.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Apollo Medical in the 2nd quarter valued at $28,267,000. Vanguard Group Inc. raised its position in Apollo Medical by 184.8% in the 3rd quarter. Vanguard Group Inc. now owns 928,911 shares of the healthcare company’s stock valued at $20,501,000 after purchasing an additional 602,710 shares during the last quarter. Northern Trust Corp purchased a new stake in Apollo Medical in the 2nd quarter valued at $6,137,000. Royce & Associates LP purchased a new stake in Apollo Medical in the 3rd quarter valued at $1,898,000. Finally, Cadence Capital Management LLC purchased a new stake in Apollo Medical in the 3rd quarter valued at $1,619,000.

Apollo Medical Company Profile

Apollo Medical Holdings, Inc is a patient-centered, physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care. The Company operates in healthcare delivery segment. Its operations include Hospitalists, which include its contracted physicians focusing on the delivery of medical care to hospitalized patients; an accountable care organization (ACO), which focuses on providing care to Medicare fee-for-service patients; an independent practice association (IPA), which contracts with physicians and provides care to Medicare, Medicaid, commercial and dual-eligible patients on a risk- and value-based fee basis; approximately three clinics, which it owns or operates, and which provide specialty care in the greater Los Angeles area, and Palliative care, home health and hospice services, which include its at-home and end-of-life services.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Apollo Medical (AMEH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apollo Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply